Opus Genetics Gains October 2026 FDA PDUFA Date, Reports Positive Gene Therapy Trial Results
IRD has more than doubled off its 52-week low of $0.65.
Summary
Opus Genetics announced a significant corporate update, highlighted by the FDA accepting its supplemental New Drug Application (sNDA) for Phentolamine Ophthalmic Solution 0.75% for presbyopia and setting an October 17, 2026 PDUFA action date. This provides a clear regulatory catalyst for a late-stage product. Additionally, the company reported favorable early safety and initial efficacy data from its Phase 1/2 OPGx-BEST1 gene therapy trial, showing an equivalent 12-letter gain in Best Corrected Visual Acuity and a 23% decrease in central subfield thickness. The company also secured new funding, extending its cash runway into 2028, significantly de-risking its operations and supporting its deep pipeline in inherited retinal diseases. These combined positive developments, including a key regulatory milestone, promising clinical data, and improved financial stability, are highly material for the company's valuation and future prospects.
At the time of this announcement, IRD was trading at $4.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $329M. The 52-week trading range was $0.65 to $5.10. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.